Editorials Folic acid fortification for Europe? BMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h6198 (Published 24 November 2015) Cite this as: BMJ 2015;351:h6198 Article Related content Metrics Responses Peer review Related articles Letter Decision on folic acid fortification in Europe must consider both risks and benefits Published: 16 February 2016; BMJ 352 doi:10.1136/bmj.i734 Letter Authors’ reply to Smith and colleagues Published: 16 February 2016; BMJ 352 doi:10.1136/bmj.i746 Research Long term trends in prevalence of neural tube defects in Europe: population based study Published: 24 November 2015; BMJ 351 doi:10.1136/bmj.h5949 ResearchLong term trends in prevalence of neural tube defects in Europe See more Gynaecology: Clinicians demand urgent support to tackle lengthy waiting lists BMJ November 18, 2024, 387 q2552; DOI: https://doi.org/10.1136/bmj.q2552 Scandal of “newborn gang” that put profits ahead of babies’ lives rocks Turkey’s health system BMJ November 07, 2024, 387 q2466; DOI: https://doi.org/10.1136/bmj.q2466 NICE reiterates importance of HRT for menopausal symptoms BMJ November 07, 2024, 387 q2460; DOI: https://doi.org/10.1136/bmj.q2460 The commercial determinants of infant and child health BMJ October 31, 2024, 387 q2395; DOI: https://doi.org/10.1136/bmj.q2395 US infant mortality rose after Supreme Court ended right to abortion BMJ October 23, 2024, 387 q2337; DOI: https://doi.org/10.1136/bmj.q2337 Cited by... Decision on folic acid fortification in Europe must consider both risks and benefitsFulltext PDF Authors reply to Smith and colleaguesFulltext PDF
